These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

456 related articles for article (PubMed ID: 25694334)

  • 1. Native mass spectrometry and ion mobility characterization of trastuzumab emtansine, a lysine-linked antibody drug conjugate.
    Marcoux J; Champion T; Colas O; Wagner-Rousset E; Corvaïa N; Van Dorsselaer A; Beck A; Cianférani S
    Protein Sci; 2015 Aug; 24(8):1210-23. PubMed ID: 25694334
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Statistical modeling of the drug load distribution on trastuzumab emtansine (Kadcyla), a lysine-linked antibody drug conjugate.
    Kim MT; Chen Y; Marhoul J; Jacobson F
    Bioconjug Chem; 2014 Jul; 25(7):1223-32. PubMed ID: 24873191
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis and evaluation of antibody-drug conjugates with high drug-to-antibody ratio using dimaleimide-DM1 as a linker- payload.
    Jeon JH; Woo Kim S; Kim YJ; Park JW; Eun Moon J; Beom Lee Y; Yu H; Lee GH; Jin SH; Jeong JH
    Bioorg Chem; 2024 Aug; 149():107504. PubMed ID: 38850783
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A mechanistic pharmacokinetic model elucidating the disposition of trastuzumab emtansine (T-DM1), an antibody-drug conjugate (ADC) for treatment of metastatic breast cancer.
    Bender B; Leipold DD; Xu K; Shen BQ; Tibbitts J; Friberg LE
    AAPS J; 2014 Sep; 16(5):994-1008. PubMed ID: 24917179
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multiple heart-cutting and comprehensive two-dimensional liquid chromatography hyphenated to mass spectrometry for the characterization of the antibody-drug conjugate ado-trastuzumab emtansine.
    Sandra K; Vanhoenacker G; Vandenheede I; Steenbeke M; Joseph M; Sandra P
    J Chromatogr B Analyt Technol Biomed Life Sci; 2016 Oct; 1032():119-130. PubMed ID: 27160547
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Understanding How the Stability of the Thiol-Maleimide Linkage Impacts the Pharmacokinetics of Lysine-Linked Antibody-Maytansinoid Conjugates.
    Ponte JF; Sun X; Yoder NC; Fishkin N; Laleau R; Coccia J; Lanieri L; Bogalhas M; Wang L; Wilhelm S; Widdison W; Pinkas J; Keating TA; Chari R; Erickson HK; Lambert JM
    Bioconjug Chem; 2016 Jul; 27(7):1588-98. PubMed ID: 27174129
    [TBL] [Abstract][Full Text] [Related]  

  • 7. LC-MS/MS method for the simultaneous determination of Lys-MCC-DM1, MCC-DM1 and DM1 as potential intracellular catabolites of the antibody-drug conjugate trastuzumab emtansine (T-DM1).
    Liu Y; Zhou F; Sang H; Ye H; Chen Q; Yao L; Ni P; Wang G; Zhang J
    J Pharm Biomed Anal; 2017 Apr; 137():170-177. PubMed ID: 28131055
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of different linkers on target cell catabolism and pharmacokinetics/pharmacodynamics of trastuzumab maytansinoid conjugates.
    Erickson HK; Lewis Phillips GD; Leipold DD; Provenzano CA; Mai E; Johnson HA; Gunter B; Audette CA; Gupta M; Pinkas J; Tibbitts J
    Mol Cancer Ther; 2012 May; 11(5):1133-42. PubMed ID: 22408268
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Innovative native MS methodologies for antibody drug conjugate characterization: High resolution native MS and IM-MS for average DAR and DAR distribution assessment.
    Debaene F; Boeuf A; Wagner-Rousset E; Colas O; Ayoub D; Corvaïa N; Van Dorsselaer A; Beck A; Cianférani S
    Anal Chem; 2014 Nov; 86(21):10674-83. PubMed ID: 25270580
    [TBL] [Abstract][Full Text] [Related]  

  • 10. LC-HRMS quantitation of intact antibody drug conjugate trastuzumab emtansine from rat plasma.
    Jin W; Burton L; Moore I
    Bioanalysis; 2018 Jun; 10(11):851-862. PubMed ID: 29863890
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biophysical Properties and Heating-Induced Aggregation of Lysine-Conjugated Antibody-Drug Conjugates.
    Gandhi AV; Arlotta KJ; Chen HN; Owen SC; Carpenter JF
    J Pharm Sci; 2018 Jul; 107(7):1858-1869. PubMed ID: 29626535
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structural Characterization of Cross-Linked Species in Trastuzumab Emtansine (Kadcyla).
    Chen Y; Kim MT; Zheng L; Deperalta G; Jacobson F
    Bioconjug Chem; 2016 Sep; 27(9):2037-47. PubMed ID: 27458087
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of Drug-Antibody Ratio on Pharmacokinetics, Biodistribution, Efficacy, and Tolerability of Antibody-Maytansinoid Conjugates.
    Sun X; Ponte JF; Yoder NC; Laleau R; Coccia J; Lanieri L; Qiu Q; Wu R; Hong E; Bogalhas M; Wang L; Dong L; Setiady Y; Maloney EK; Ab O; Zhang X; Pinkas J; Keating TA; Chari R; Erickson HK; Lambert JM
    Bioconjug Chem; 2017 May; 28(5):1371-1381. PubMed ID: 28388844
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Near-Infrared Photochemoimmunotherapy by Photoactivatable Bifunctional Antibody-Drug Conjugates Targeting Human Epidermal Growth Factor Receptor 2 Positive Cancer.
    Ito K; Mitsunaga M; Nishimura T; Saruta M; Iwamoto T; Kobayashi H; Tajiri H
    Bioconjug Chem; 2017 May; 28(5):1458-1469. PubMed ID: 28402624
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cutting-edge mass spectrometry methods for the multi-level structural characterization of antibody-drug conjugates.
    Beck A; Terral G; Debaene F; Wagner-Rousset E; Marcoux J; Janin-Bussat MC; Colas O; Van Dorsselaer A; Cianférani S
    Expert Rev Proteomics; 2016; 13(2):157-83. PubMed ID: 26653789
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In-depth structural characterization of Kadcyla® (ado-trastuzumab emtansine) and its biosimilar candidate.
    Chen L; Wang L; Shion H; Yu C; Yu YQ; Zhu L; Li M; Chen W; Gao K
    MAbs; 2016 Oct; 8(7):1210-1223. PubMed ID: 27380163
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Middle-Down Multi-Attribute Analysis of Antibody-Drug Conjugates with Electron Transfer Dissociation.
    Chen B; Lin Z; Zhu Y; Jin Y; Larson E; Xu Q; Fu C; Zhang Z; Zhang Q; Pritts WA; Ge Y
    Anal Chem; 2019 Sep; 91(18):11661-11669. PubMed ID: 31442030
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Conjugation site analysis of antibody-drug-conjugates (ADCs) by signature ion fingerprinting and normalized area quantitation approach using nano-liquid chromatography coupled to high resolution mass spectrometry.
    Sang H; Lu G; Liu Y; Hu Q; Xing W; Cui D; Zhou F; Zhang J; Hao H; Wang G; Ye H
    Anal Chim Acta; 2017 Feb; 955():67-78. PubMed ID: 28088282
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ado-trastuzumab emtansine (T-DM1): a novel antibody-drug conjugate for the treatment of HER2-positive metastatic breast cancer.
    Baron JM; Boster BL; Barnett CM
    J Oncol Pharm Pract; 2015 Apr; 21(2):132-42. PubMed ID: 24682654
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aberrant intracellular metabolism of T-DM1 confers T-DM1 resistance in human epidermal growth factor receptor 2-positive gastric cancer cells.
    Wang H; Wang W; Xu Y; Yang Y; Chen X; Quan H; Lou L
    Cancer Sci; 2017 Jul; 108(7):1458-1468. PubMed ID: 28388007
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.